Trial Profile
A Phase III Open Label, Multi-Center Pediatric Study in China Comparing Booster Doses of Vaxem Hib and Hiberix Vaccines for the Prevention of Haemophilus Influenzae Type b (Hib) Infection.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jun 2013
Price :
$35
*
At a glance
- Drugs TAK 816 (Primary) ; Hib vaccine conjugate
- Indications Haemophilus infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Novartis
- 29 Jul 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov (NCT01025544).
- 29 Jul 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov (NCT01025544).
- 02 Dec 2009 Booster trial identified and integrated (NCT01025544).